Currently, the clinical effectiveness and safety profile of vorasidenib (AG-881), the first dual inhibitor of mIDH1 and mIDH2, in the treatment of glioma with IDH1/IDH2 mutation are being investigated [24]. This evidence concerns the gene IDH2 and central nervous system cancer.